全文获取类型
收费全文 | 6286篇 |
免费 | 677篇 |
国内免费 | 296篇 |
专业分类
耳鼻咽喉 | 34篇 |
儿科学 | 147篇 |
妇产科学 | 83篇 |
基础医学 | 1591篇 |
口腔科学 | 248篇 |
临床医学 | 535篇 |
内科学 | 1025篇 |
皮肤病学 | 170篇 |
神经病学 | 347篇 |
特种医学 | 93篇 |
外国民族医学 | 3篇 |
外科学 | 408篇 |
综合类 | 932篇 |
现状与发展 | 1篇 |
预防医学 | 216篇 |
眼科学 | 120篇 |
药学 | 613篇 |
中国医学 | 368篇 |
肿瘤学 | 325篇 |
出版年
2024年 | 10篇 |
2023年 | 72篇 |
2022年 | 136篇 |
2021年 | 210篇 |
2020年 | 252篇 |
2019年 | 166篇 |
2018年 | 182篇 |
2017年 | 222篇 |
2016年 | 235篇 |
2015年 | 249篇 |
2014年 | 338篇 |
2013年 | 523篇 |
2012年 | 319篇 |
2011年 | 406篇 |
2010年 | 346篇 |
2009年 | 359篇 |
2008年 | 360篇 |
2007年 | 361篇 |
2006年 | 341篇 |
2005年 | 346篇 |
2004年 | 322篇 |
2003年 | 262篇 |
2002年 | 208篇 |
2001年 | 207篇 |
2000年 | 172篇 |
1999年 | 135篇 |
1998年 | 114篇 |
1997年 | 92篇 |
1996年 | 90篇 |
1995年 | 76篇 |
1994年 | 64篇 |
1993年 | 41篇 |
1992年 | 22篇 |
1991年 | 11篇 |
1990年 | 4篇 |
1989年 | 2篇 |
1988年 | 2篇 |
1987年 | 1篇 |
1985年 | 1篇 |
排序方式: 共有7259条查询结果,搜索用时 15 毫秒
991.
《Expert opinion on therapeutic targets》2013,17(10):1023-1027
Periodontitis is characterized by gingival inflammation and periodontopathic bacteria generate immunological inflammatory responses. Recent epidemiological reports suggest that periodontitis is one of the key risk factors for the onset of cardiovascular diseases. Several studies reported that periodontal bacteria in cardiovascular specimens were frequently detected. We revealed that patients with acute coronary syndrome showed significantly higher serum IgG titers to a strain of periodontopathic bacteria compared with patients with chronic coronary disease. Periodontopathic bacteria were also present in a high percentage of specimens of diseased arteries from patients with Buerger disease or abdominal aortic aneurysm. Although periodontopathic bacteria may play a role in the development of cardiovascular diseases, the influence of these bacteria on the disease has not yet been proven. In this article, we review the relationship between periodontopathic pathogens and cardiovascular diseases to conduct further clinical and experimental investigations in near future. 相似文献
992.
《Expert opinion on therapeutic patents》2013,23(9):1257-1271
Eczematous skin diseases such as atopic dermatitis and allergic contact dermatitis are common and are characterised by the appearance of oozing, erythema, crusting, papules and, in long standing lesions, lichenification. After the successful introduction of the topical immunomodulators as a new topical therapy of atopic eczema, several other therapeutic compounds have been developed in the last 2 years. These are presented in this article based on recent patents. Primarily, developments for the treatment of pruritus and inflammation are molecules affecting the H4-receptor, the cannabinoid receptors and the prostanoid receptors, but antagonists targeting PDE4, CCR-1 or -3, or chemoattractants have also been developed. The latest patents on glucocorticosteroids and their compositions are discussed, also, the antibody-derived and cytokine-targeted therapeutical agents. In the latter case, however, the number of patents has decreased due to their time-consuming and cost-intensive production. Furthermore, one interesting patent deals with improvement of the skin barrier function and enhancement of epidermal cohesion through stratum corneum acidification. Finally, new photosensitisers or pro-photosensitisers for photodynamic therapy to treat T-cell-mediated skin disorders have been claimed. However, most of the discussed developments will need application of clinical efficacy and safety in the near future. 相似文献
993.
《Expert opinion on investigational drugs》2013,22(7):1067-1086
Chronic obstructive pulmonary disease is a major health problem with cigarette smoking as its major risk factor. Current therapies are directed against the symptoms (e.g., breathlessness and mucus production) or the chronic airway inflammation. However, the excessive annual decline in lung function and the airway inflammation have not yet been shown to be improved by these strategies. New potential drug therapies are directed against specific components of the inflammation. Novel drugs have been developed for treatment of inflammatory diseases including chronic obstructive pulmonary disease in order to antagonise cytokines and chemokines such as TNF-α, CXC chemokine ligand 8 (IL-8) or CC chemokine ligand 2 (monocyte chemoattractant protein 1) that orchestrate the inflammatory process. Some of these drugs are shown to be effective in patients with other chronic inflammatory diseases but still have to prove their efficacy in the treatment of chronic obstructive pulmonary disease. 相似文献
994.
《Expert opinion on investigational drugs》2013,22(7):935-950
The treatment of neuropathic pain is a major unresolved medical challenge. Present pharmacotherapies only have modest efficacy and numerous side effects. The use of opioid analgesics is additionally coupled with dependence and withdrawal syndromes. Ibudilast (AV-411) is a non-selective phosphodiesterase inhibitor that is also known to suppress glial cell activation. It has been used clinically for other indications with a good safety profile. As glial cell activation is considered to crucially contribute to neuropathic pain as well as opioid dependence and withdrawal, the authors conceived that ibudilast may be useful for treating these conditions. Preclinical data indicate that ibudilast crosses the blood–brain barrier, is well tolerated, is active on oral administration, reduces glial activation and attenuates pain symptoms in diverse rat models of neuropathic pain. In addition, it enhances acute morphine analgesia and attenuates morphine tolerance and withdrawal. Thus ibudilast may improve opioid efficacy and is a promising therapeutic candidate for neuropathic pain, with a novel mechanism of action. 相似文献
995.
Yue Shi Xiao-chun Liang Hong Zhang Qun-li Wu Ling Qu Qing Sun 《Acta pharmacologica Sinica》2013,34(9):1140-1148
Aim:
To examine the effects of quercetin, a natural antioxidant, on high glucose (HG)-induced apoptosis of cultured dorsal root ganglion (DRG) neurons of rats.Methods:
DRG neurons exposed to HG (45 mmol/L) for 24 h were employed as an in vitro model of diabetic neuropathy. Cell viability, reactive oxygen species (ROS) level and apoptosis were determined. The expression of NF-кB, IкBα, phosphorylated IкBα and Nrf2 was examined using RT PCR and Western blot assay. The expression of hemeoxygenase-1 (HO-1), IL-6, TNF-α, iNOS, COX-2, and caspase-3 were also examined.Results:
HG treatment markedly increased DRG neuron apoptosis via increasing intracellular ROS level and activating the NF-κB signaling pathway. Co-treatment with quercetin (2.5, 5, and 10 mmol/L) dose-dependently decreased HG-induced caspase-3 activation and apoptosis. Quercetin could directly scavenge ROS and significantly increased the expression of Nrf-2 and HO-1 in DRG neurons. Quercetin also dose-dependently inhibited the NF-κB signaling pathway and suppressed the expression of iNOS, COX-2, and proinflammatory cytokines IL-6 and TNF-α.Conclusion:
Quercetin protects rat DRG neurons against HG-induced injury in vitro through Nrf-2/HO-1 activation and NF-κB inhibition, thus may be beneficial for the treatment of diabetic neuropathy. 相似文献996.
997.
《Pharmaceutical biology》2013,51(10):1262-1271
AbstractContext. Tephrosia toxicaria is currently known as Tephrosia sinapou (Buc'hoz) A. Chev. (Fabaceae) and is a source of compounds such as flavonoids that inhibit inflammatory pain.Objective: To investigate the analgesic effect and mechanisms of the ethyl acetate extract of T. sinapou in inflammatory pain in mice.Materials and methods: Behavioral responses were evaluated using mechanical (1–24?h) and thermal hyperalgesia (0.5–5?h), writhing response (20?min) and rota-rod (1–5?h) tests. Neutrophil recruitment (myeloperoxidase activity), cytokines (tumor necrosis factor [TNF]α and interleukin [IL]-1β), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) serum levels were determined by colorimetric assays. Pharmacological treatments were opioid receptor antagonist (naloxone, 0.1–1?mg/kg) and control opioid (morphine, 5?mg/kg). Inflammatory stimuli were carrageenin (100?µg/paw), complete Freund’s adjuvant (CFA, 10?µl/paw), prostaglandin E2 (PGE2, 100?ng/paw) and acetic acid (0.8%).Results: The intraperitoneal pre-treatment with extract inhibited in a dose-dependent (30–300?mg/kg) dependent manner the mechanical hyperalgesia induced by carrageenin (up to 93% inhibition). The post-treatment (100?mg/kg) inhibited CFA-induced hyperalgesia (up to 63% inhibition). Naloxone (1?mg/kg) prevented the inhibitory effect of the extract over carrageenin-induced mechanical (100%) and thermal (100%) hyperalgesia, neutrophil recruitment (52%) and TNFα (63%) and IL-1β (98%) production, thermal threshold in naïve mice (99%), PGE2-induced mechanical hyperalgesia (88%) and acetic acid-induced writhing response (49%). There was no significant alteration in the rota-rod test, and AST and ALT serum levels by extract treatment.Discussion and conclusion. Tephrosia sinapou ethyl acetate extract reduces inflammatory pain by activating an opioid receptor-dependent mechanism. 相似文献
998.
《Expert opinion on pharmacotherapy》2013,14(9):1437-1448
Over the past two decades, the underlying pathophysiology of haemophagocytic lymphohistiocytosis (HLH) (synonyms: haemophagocytic syndrome, macrophage activation syndrome) has been well recognised. Cytokine storm plays a major role, which derives from an inappropriate immune reaction caused by proliferating and activated T-cell or natural killer (NK) cells associated with macrophage activation and inadequate apoptosis of immunogenic cells. Many biological parameters reflecting activity of disease or response to treatment have been identified, in particular, serum ferritin has been confirmed to be one of the markers for HLH. The common types of HLH consist of non-hereditary (acquired) infection-associated disease such as Epstein-Barr virus (EBV)-haemophagocytic lymphohistiocytosis (HLH) and hereditary (familial) disease such as FHL, in which, at the molecular level, dysfunctional perforin was clarified. Regarding the therapeutic strategies, prompt differential diagnosis of underlying disease is essential and choice of treatment should be based on the risk (low or high) of prognosis, where either cyclosporin A, steroids or iv. immunoglobulin (IVIG) may be indicated as initial treatment for low-risk patients, with etoposide-containing regimens for high-risk patients. Significant improvement of prognosis has been obtained by incorporating intensive supportive care at the disease onset and prompt introduction of immunosuppressants to control cytokine storm. Subsequent immunochemotherapy and haemopoietic stem cell transplantation have contributed significantly to further improve survival of hereditary and refractory HLH patients. 相似文献
999.
《Expert opinion on emerging drugs》2013,18(1):159-174
Background: The prevalence of end-stage liver disease is rising rapidly and constitutes a major healthcare burden currently. Many cases are diagnosed at a later stage when liver transplantation is the only effective treatment option. There is thus an urgent need for novel treatments to reverse the earlier stages of cirrhosis as well as to treat the many associated life-threatening complications. Objectives: To review the current drugs available for treating the complications of advanced liver disease. To address novel treatment strategies that are in development, with particular reference to the rapidly developing area of antifibrotic therapy. To assess how the obstacles that have so far impeded the development of effective new drugs for end-stage liver disease may be overcome in the future. Methods: The literature was reviewed to define current therapies and therapies in clinical trials. We used the current models of the molecular basis of liver fibrogenesis to determine potential new therapeutic targets for antifibrotic therapy. Conclusions: Insights into the pathogenesis of liver injury and fibrosis have opened up new avenues for therapy and there are now candidates and targets with real potential for the development of a new generation of antifibrotic therapies. 相似文献
1000.
Sreenivas Pandit Erdal Cevher Mohammed Gulrez Zariwala Satyanarayana Somavarapu Professor H. Oya Alpar 《Journal of microencapsulation》2013,30(6):539-552
Purpose: Poly (L-lactic acid) (PLA) microparticles encapsulating Hepatitis B surface antigen (HBsAg) with alum and chitosan were investigated for their potential as a vaccine delivery system.Methods: The microparticles, prepared using a water-in-oil-in-water (w/o/w) double emulsion solvent evaporation method with polyvinyl alcohol (PVA) or chitosan as the external phase stabilising agent showed a significant increase in the encapsulation efficiency of the antigen.Results: PLA-Alum and PLA-chitosan microparticles induced HBsAg serum specific IgG antibody responses significantly higher than PLA only microparticles and free antigen following subcutaneous administration. Chitosan not only imparted a positive charge to the surface of the microparticles but was also able to increase the serum specific IgG antibody responses significantly.Conclusions: The cytokine assays showed that the serum IgG antibody response induced is different according to the formulation, indicated by the differential levels of interleukin 4 (IL-4), interleukin 6 (IL-6) and interferon gamma (IFN-γ). The microparticles eliciting the highest IgG antibody response did not necessarily elicit the highest levels of the cytokines IL-4, IL-6 and IFN-γ. 相似文献